Lung lesions segmentation on CT scans

AI tool detection of potential melanoma metastases

Early and precise detection of lung lesions in CT scans is critical for diagnosing melanoma metastases. AI segmentation technique enhances accuracy and efficiency.

Challenge

The client required a reliable, automated method to detect and characterize lung lesions while accounting for the unique properties of lung CT scans.

Approach

  • Developed segmentation models optimized for lung CT scans.
  • Utilized SOTA computer vision techniques for enhanced accuracy.

Results

  • Automated lesion detection, improving melanoma metastasis identification.
  • Enabled quantification of radiomic features for lesion characterization.

This AI supported approach improves early melanoma detection, supporting timely and effective treatment decisions.

Expert Contribution

Reviewed by: Dr. Krzysztof Kolmus, PhD
Role: Lead Bioinformatician, AI‑Driven Drug Discovery
Expertise: Biomarker discovery, target identification, multi‑omics data analysis, translational bioinformatics

Want to achieve similar efficiency gains? Let's discuss how we can optimize your clinical project.

You might be also interested in:

Life sciences conference takeaways 2026 - AACR, PEGS Boston, SLAS Europe, and Bio-IT World summary on AI in drug discovery
What 4 Life Sciences Conferences Revealed About AI in Drug Discovery
Life sciences professional using a tablet in front of digital data infrastructure screens
Scaling AI in Life Sciences: Why Data Infrastructure Determines Success
Large Language Model platform for patient-friendly content
lab-in-the-loop drug discovery
The 49% Problem: Why Closing the Lab-AI Loop Starts Beneath the Iceberg

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!